Exact Sciences Completes Enrollment of DeeP-C Clinical Trial for Colorectal Cancer Screening

More than 12,700 patients enrolled to evaluate the company’s non-invasive stool-based DNA test to detect the second leading cause of cancer deaths.

MADISON, WI. – Exact Sciences Corp. (Nasdaq: EXAS) today announced it has completed patient enrollment in its DeeP-C pivotal trial for colorectal cancer screening. The study enrolled more than 12,700 patients at sites in the United States and Canada.

Read More